Marek Poszepczynski
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Marek Poszepczynski
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden.
9
| Extinct | Miscellaneous Commercial Services | 9 |
| Public Company | Pharmaceuticals: Major | 9 | |
| Public Company | Major Banks | 9 | |
| Public Company | Financial Conglomerates | 6 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Marek Poszepczynski tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chairman Chairman | |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
EffRx Pharmaceuticals SA
 EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
| KARO PHARMA AB (PUBL) | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| BIOINVENT INTERNATIONAL AB | Biotechnology | Director/Board Member Director/Board Member | |
| ACTIVE BIOTECH AB | Biotechnology | Director/Board Member Director/Board Member | |
| MEDA AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| MEDIVIR AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal | |
Industrifonden
 Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | Investment Managers | Director of Investments Director/Board Member Consultant / Advisor | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Hartwall Capital Oy Ab
 Hartwall Capital Oy Ab Investment ManagersFinance Hartwall Capital Oy Ab (Hartwall Capital) is a private equity firm subsidiary of Hartwall Family founded in 1988. The firm is headquartered in Helsinki, Finland. | Investment Managers | Chairman Chairman | |
| University of Uppsala | College/University | Wenche Nelly A. Rolfsen Sandsborg | Doctorate Degree Doctorate Degree Graduate Degree Masters Business Admin Doctorate Degree Undergraduate Degree |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor Private Equity Investor Chief Executive Officer | |
| INDEX PHARMACEUTICALS HOLDING AB | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Arexis AB
 Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| University of Stockholm | College/University | Graduate Degree Graduate Degree | |
| WEIFA ASA | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
| Royal Institute of Technology | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree Graduate Degree | |
| University of Lund | College/University | Graduate Degree Corporate Officer/Principal Corporate Officer/Principal | |
| VIVESTO AB | Pharmaceuticals: Generic | Public Communications Contact Director/Board Member | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| BONESUPPORT HOLDING AB | Medical Specialties | Director/Board Member Director/Board Member | |
| MOBERG PHARMA AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| AROCELL AB | Medical Specialties | Director/Board Member Chief Executive Officer | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
| BIOARCTIC AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| KCIF Fund Management AB | Director/Board Member Chairman | ||
SwedenBIO Service AB
 SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Founder Chairman | |
| BERGENBIO ASA | Pharmaceuticals: Major | Corporate Officer/Principal Chairman | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer Director/Board Member Chairman | |
| Hanken Svenska Handelshögskolan | College/University | Undergraduate Degree Graduate Degree | |
| Aprea Personal AB | Director/Board Member Chairman | ||
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Chairman | |
BONE SUPPORT AB
 BONE SUPPORT AB Medical SpecialtiesHealth Technology BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden. | Medical Specialties | Director/Board Member Director/Board Member | |
Sixera Pharma AB
 Sixera Pharma AB Pharmaceuticals: GenericHealth Technology Sixera Pharma AB conducts activities within research, development, and commercialization of pharmaceuticals. It develops treatment for Netherton syndrome. The company was founded by Jean Nordstrom on August 21, 2012 and is headquartered in Göteborg, Sweden. | Pharmaceuticals: Generic | Founder Chief Tech/Sci/R&D Officer | |
Cinclus Pharma AG
 Cinclus Pharma AG BiotechnologyHealth Technology Cinclus Pharma AG is a Swiss Swedish pharmaceutical company founded in 2011. Cinclus Pharma is based in Basel, Switzerland. The private company is focused on bringing relief to people suffering from gastric acid related diseases, particularly gastroesophageal reflux disease (GERD). Cinclus Pharma's clinical stage drug candidate, linaprazan glurate, is a new approach to managing GERD and is showing promising results in acid control and lowering the cmax-value. The company was founded by experts in the field of GERD treatment with extensive experience from Astra and Astra Zeneca. | Biotechnology | Director/Board Member Director/Board Member | |
Cinclus Pharma Holding AB
 Cinclus Pharma Holding AB BiotechnologyHealth Technology Cinclus Pharma Holding AB is a Swedish pharmaceutical company that focuses on developing clinical stage drug candidates for gastric acid related diseases. The company's drug candidate, linaprazan glurate, takes a new approach to provide improved management of GERD. Gastroesophageal reflux disease, or acid reflux, is a condition in which the content of the stomach regurgitates into the esophagus. The company was founded by pioneers in GERD treatment with extensive experience from Astra and Astra Zeneca. Christer Ahlberg has been the CEO of the company since 2021. | Biotechnology | Chairman Director/Board Member |
Statistiche
Distribuzione geografica
| Svezia | 40 |
| Stati Uniti | 4 |
| Svizzera | 3 |
| Finlandia | 3 |
| Norvegia | 3 |
Settori
| Health Technology | 33 |
| Consumer Services | 7 |
| Commercial Services | 6 |
| Finance | 4 |
Posizioni
| Director/Board Member | 297 |
| Chairman | 98 |
| Corporate Officer/Principal | 96 |
| Independent Dir/Board Member | 69 |
| Chief Executive Officer | 57 |
Contatti più connessi
- Borsa valori
- Insiders
- Marek Poszepczynski
- Connessioni Società
